drugset / Trial / NCT01981499
A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults
RandomizedCrossoverDouble-blindBasic science
Summary
PF-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce vascular permeability. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and effects on histamine-induced wheal of single doses of PF-05180999 in healthy adult subjects. Histamine-induced wheals are biomarkers of vascular permeability.
Timeline
- Start
- 2014-01
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-05180999 | Small molecule | 120 mg | Oral |
| Subject | PF-05180999 | Small molecule | 240 mg | Oral |
| Subject | PF-05180999 | Small molecule | 360 mg | Oral |
| Subject | PF-05180999 | Small molecule | 420 mg | Oral |
| Background | Cetirizine | Other / unclassified | 10 mg | — |